Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis (NCT06975787)
A Dose Escalation Study Investigating Bispecific Antibody Therapy in Patients With Lupus Nephritis
🩺 Plain-English Summary (8th-Grade Level)
This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN). The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up. This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic — Rochester, Minnesota
Age range: 18 Years to 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Mayo Clinic — Rochester, Minnesota
- Baylor College of Medicine — Houston, Texas
- Centre Hospitalier Universitaire (CHU) Bordeaux — Bordeaux, New Aquitaine
- University Hospital Regensburg — Regensburg, Bavaria
- University Medical Center of the Johannes Gutenberg-University Mainz — Mainz,
- Hallym University Sacred Heart Hospital — Anyang-si, Gyeonggi-do
- Seoul National University Hospital — Seoul,
- Samsung Medical Center — Seoul,
- Yonsei University College of Medicine, Severance Hospital — Seoul,
- Hospital Universitario Virgen del Rocio — Seville, Andalusia
- Clinica Universidad de Navarra — Pamplona, Navarre
- Hospital Gregorio Maranon — Madrid,
- Hospital Universitario 12 de Octubre — Madrid,
- Hospital Regional Universitario de Malaga — Málaga,
- Changhua Christian Hospital — Changhua,
- Taichung General Veterans Hospital — Taichung,
- National Taiwan University Hospital — Taipei,
- Taipei Veterans General Hospital — Taipei,
📞 Contact the Study Coordinator
Phone: (844) 734-6643
Email: clinicaltrials@regeneron.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lupus Nephritis (LN)
- Safety and Efficacy of ONT01 in Lupus — New York, New York
- Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis — Guadalajara, Jalisco
- Dapagliflozin in Active Lupus Nephritis — Boston, Massachusetts
Explore by condition: All Lupus Nephritis (LN) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.